Randomized, open-label, prospective clinical trial assessing efficacy and safety on
hyperlipidemia of a switching from a regimen including one
protease inhibitor and one
thymidine analogue to
atazanavir/
ritonavir plus
abacavir/lamivudine or
tenofovir/
emtricitabine. Adult HIV-infected patients on their first antiretroviral
therapy (of at least 48-week duration), including one
protease inhibitor and
zidovudine or
stavudine, with stable immunovirologic features, and having diagnosis of persisting
hyperlipidemia, were randomized to replace current treatment with
atazanavir/
ritonavir plus
abacavir/lamivudine (arm A) or
tenofovir/
emtricitabine (arm B), and were followed for 48 weeks. Eighty-nine patients were enrolled: 42 patients were randomized to arm A, and 47 to arm B. At the end of the 48-week follow-up, incidence of virologic failure was comparable in both arms, and associated with a poor drug compliance. Increase in CD4 lymphocyte count was significantly higher in arm A after a 24-week study period (62.5 versus 39.2 x 10(6) cells/L; p < 0.05), while immunologic responses were comparable at the end of 48-week follow-up (91.5 versus 83.6; p > 0.05). A statistically significant reduction (-15.4%) in mean triglyceridaemia versus respective baseline values was reported in both groups (p < 0.05), without statistically significant difference between arm A and B. Similar results were reported for total
cholesterol and
low-density lipoprotein (
LDL) cholesterol levels. Safety and tolerability profiles were comparable in both groups. Switching from a
protease inhibitor- and
thymidine analogue-based antiretroviral regimen to
atazanavir/
ritonavir plus
abacavir/lamivudine or
tenofovir/
emtricitabine proved effective in the management of
hyperlipidemia, without significant differences in
lipid-lowering effect, virologic efficacy, and safety profile between these regimens.